TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Key Inclusion Criteria:~* Body weight ≥35 kg.~* Subjects must have an eligibleCFTR genotype.~  * Part 1 and Part 3: Heterozygous for F508del and an MF mutation (F/MF)~ * Part 2: Homozygous for F508del (F/F)~* FEV1 value ≥40% and ≤90% of predicted mean for age, sex, and height~Key Exclusion Criteria:~* History of clinically significant cirrhosis with or without portal hypertension.~* Glucose-6-phosphate dehydrogenase (G6PD) deficiency~* Lung infection with organisms associated with a more rapid decline in pulmonary status.~* History of solid organ or hematological transplantation.~Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo matched to VX-659/TEZ/IVA in TC treatment period for 4 weeks and placebo matched TEZ/IVA in washout period for 4 days.
- Part 1: VX-659/TEZ/IVA TC - Low Dose (Type: EXPERIMENTAL): Participants received VX-659 80 milligram (mg) once daily (qd)/TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
- Part 1: VX-659/TEZ/IVA TC - Medium Dose (Type: EXPERIMENTAL): Participants received VX-659 240 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
- Part 1: VX-659/TEZ/IVA TC - High Dose (Type: EXPERIMENTAL): Participants received VX-659 400 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 days.
- Part 2: TEZ/IVA (Type: ACTIVE_COMPARATOR): Following run-in period with TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks, participants received TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 weeks.
- Part 2: VX-659/TEZ/IVA TC (Type: EXPERIMENTAL): Following run-in period with TEZ 100 mg qd/IVA 150 mg q12h for 4 weeks, participants received VX-659 400 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in TC treatment period for 4 weeks and TEZ 100 mg qd/IVA 150 mg q12h in washout period for 4 weeks.
- Part 3: Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo matched to VX-659/TEZ/VX-561 in TC treatment period for 4 weeks.
- Part 3: VX-659/TEZ/VX-561 TC (Type: EXPERIMENTAL): Participants received VX-659 400 mg qd/TEZ 100 mg qd/VX-561 200 mg qd in TC treatment period for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Genicular Nerve Block for Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects scheduled for primary elective total knee arthroplasty~* American Society of Anesthesiologists Physical Status I-III~* BMI 18-40 kg/m2~Exclusion Criteria:~* Inability to cooperate with protocol~* Inability to understand or speak English~* Allergy to ropivacaine, bupivacaine or other local anesthetic~* Contraindication to peripheral nerve block (e.g. local infection, neurologic deficit or disorder, previous trauma or surgery to ipsilateral knee, etc.)~* Revision knee surgery~* Chronic opioid consumption (daily morphine equivalent of \>30 mg for at least four weeks prior to surgery)~* History of chronic pain~* History of psychiatric disorder~* History of diabetes mellitus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Genicular nerve block with bupivacaine (Type: ACTIVE_COMPARATOR): The ultrasound-guided genicular nerve block will be performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler will be used to identify the arterial structures which serve as landmarks for the corresponding nerves.~After skin local anesthetic infiltration, a 10 cm 21G insulated block needle will be inserted and aligned with the ultrasound scanning plane. Once satisfactory position of the needle is confirmed, 5mL of a solution containing 15 ml 0.25% bupivacaine with 2mg dexamethasone or 5mL saline will be slowly injected. Spread of local anesthetic will be documented adjacent to the target nerve. This procedure will be performed at the site of the three genicular nerves described.
- Genicular nerve block with saline (Type: PLACEBO_COMPARATOR): The ultrasound-guided genicular nerve block will be performed at the site of the superior lateral, the superior medial, and the inferior medial genicular nerves. Color Doppler will be used to identify the arterial structures which serve as landmarks for the corresponding nerves.~After skin local anesthetic infiltration, a 10 cm 21G insulated block needle will be inserted and aligned with the ultrasound scanning plane (in-plane approach). Once satisfactory position of the needle time is confirmed, 5mL of a saline will be slowly injected. Spread of local anesthetic will be documented adjacent to the target nerve. This procedure will be performed at the site of the three genicular nerves described.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed papillary thyroid carcinoma, including its variants, such as tall cell PTC or poorly differentiated thyroid carcinoma, that is metastatic or unresectable AND harbors a BRAF V600E mutation~* Evaluable disease, as defined by at least one lesion that can be accurately measured in at least one dimension on CT scan or ultrasound, if present in the neck~* Radioiodine-refractory disease~* Life expectancy \> 6 months~* Able to swallow and retain oral medication~* Normal organ and marrow function~Exclusion Criteria:~* Pregnant or breastfeeding~* Previous treatment with a specific BRAF or MEK inhibitor~* Receiving any other study agents~* Known brain metastases~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to GSK2118436, bovine TSH, mannitol or iodine~* Active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs~* History of known glucose-6-phosphate dehyrogenase (G6PD) deficiency~* Corrected QT interval \>/= 480 msecs; history of acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting within the past 24 weeks; Class II, III, or IV heart failure, abnormal cardiac valve morphology; or history of known cardiac arrhythmias~* Taking herbal remedies~* Subjects with significant symptoms from their thyroid cancer, or have a large burden of rapidly progressive iodine-refractory PTC who are in need of other systemic therapy, as judged by their treating physician~* Uncontrolled current illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled hypertension or psychiatric illness/social situations that would limit compliance with study requirements~* History of a different malignancy unless disease-free for at least 5 years and deemed to be at low risk for recurrence~* HIV-positive on combination antiretroviral therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK2118436 (Type: EXPERIMENTAL): Intervention: GSK2118436 (dabrafenib) 150mg by mouth twice per day for 28 days, continued to day 42 if the Day 25 Iodine-131 scan shows new uptake. Patients with new Iodine-131 uptake on Day 25 who continue dabrafenib to day 42 receive a treatment dose (150 mCi) of Iodine-131 on Day 37.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
PROTOCOL ENTRY CRITERIA:~--Disease Characteristics--~* Diagnosis of macrocystic lymphangioma of the head and/or neck Cystic spaces at least 2.0 mL confirmed by radiographic imaging (MRI or CT) Mixed lymphangiomas (macrocystic and microcystic disease) allowed if macrocystic component comprises at least 50% of the total disease burden~* No mixed hemangioma-lymphangioma lesions~* At least 6 months since prior surgery for lymphangioma~--Patient Characteristics--~* Hematopoietic: No clinically significant hematologic disease No hemodynamic instability~* Hepatic: No clinically significant hepatic disorder~* Renal: No clinically significant renal disease No personal or family history of post-streptococcal glomerulonephritis~* Cardiovascular: No personal or family history of rheumatic heart disease~* Pulmonary: No respiratory failure~Other:~* Not pregnant or nursing~* Negative pregnancy test~* No history of allergy to penicillin~* No concurrent temperature of 100.5 degrees or greater~* No active upper respiratory infection~* No personal or family history of obsessive-compulsive or tic disorders~* No personal or family history of PANDA (pediatric autoimmune neuro- psychiatric disorder associated with streptococcal infections)~* No history of hypersensitivity to iodine, Omnipaque, or gadolinium (if fluoroscopy is considered necessary)~* No history of poor health (including congenital disorders, chronic diseases, or immunologic dysfunction)

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Paclitaxel in Patients With Ovarian Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological confirmed epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer.~* Patients relapsing \> 6 months after end of first line or second line treatment including platinum based therapy. Prior therapy and duration of response will be documented in the CRF for descriptive analysis.~* CA 125 \>2 x upper normal limit (UNL) documented at two occasions, with more than one week interval, according to appendix I, patient groups A and B, measurable/non- measurable disease.~* Age \> 18 years~* Eastern Cooperative Oncology Group (ECOG) performance score 0-2~* Life expectancy \>12 weeks~* Patient has blood counts at baseline of:~  * Absolute neutrophil count (ANC) \>1,5 x 109 / L.~ * Platelet count \>100 x 109 / L~ * Haemoglobin (Hb) ≥9g/dl (can be post transfusion)~* Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) \< 2 x UNL~* Total bilirubin ≤1.5 x UNL.~* Adequate renal function defined as serum creatinine \< 2.0 mg/dl or 177μmol/l.~* Alkaline phosphatase (ALP) \< 2.5 x UNL~* Signed informed consent obtained~Exclusion Criteria:~* Patient has peripheral neuropathy of grade ≥ 2 per NCI-CTCAE version 3.0~* Surgical procedure due to progressive disease within 4 weeks of any of the CA-125 measurements~* Patient receiving concurrent hormonal, immuno-, or radiotherapy. Treatment must have stopped for at least 4 weeks before start of drug treatment (Day 1, Cycle 1).~* Bowel obstruction at screening~* Tumours of other origin or histology~* Patient of child-bearing potential, not practising adequate contraception, or pregnant or lactating women~* Patient has a history of severe allergy or severe hypersensitivity to study drugs~* Any uncontrolled medical problem that in the opinion of the investigator would preclude safe administration of the study drugs, e.g. heart, lung or kidney disease, suspicion of brain metastasis or mental disorder to make the patient unable to participate in the study~* Participation in an investigational drug study within 4 weeks prior to study treatment (Day 1, Cycle 1)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paclitaxel, micellar (Paclical®) (Type: EXPERIMENTAL): None
- Paclitaxel, CrEL (Taxol®) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Four Drug Regimens for the Prevention of Malaria in Senegalese Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Ages 1 - 5 years~* Residence in the study area~* Informed consent~Exclusion Criteria:~* Known allergy to study drugs~* Chronic, underlying illness

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 5 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Drug Use Investigation of Somatropin for GHD-ADULTS.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~The patients who were administered Somatropin to treat Adult growth hormone deficiency (limited to severe type).~Exclusion Criteria:~Patients not administered Somatropin.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Somatropin (Type: None): Patients administered Somatropin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Clindamycin / Benzoyl Peroxide Gel in Subjects With Acne

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Be 12 to 45 years of age, inclusive, and in good general health.~* Clinical diagnosis of acne vulgaris~* Females of childbearing potential participating in the study must agree to use a medically acceptable method of contraception while receiving protocol-assigned product.~* Have the ability and willingness to follow all study procedures, attend all scheduled visits, and successfully complete the study.~* Have the ability to understand and sign a written informed consent form, which must be completed prior to study specific tasks being performed. Subjects under the legal age of consent in the state/province/country where the study is conducted must provide assent and have the written informed consent of a parent or guardian.~Exclusion Criteria:~* Are pregnant or breast-feeding.~* Have a history or presence of other conditions that may increase the risk of the subject participating in the study and/or affect the evaluated outcomes.~* Used topical antibiotics on the face or used systemic antibiotics within the past 2 weeks.~* Used topical corticosteroids on the face or systemic corticosteroids within the past 4 weeks. Use of inhaled, intra-articular, or intra-lesional steroids other than for facial acne is acceptable.~* Used systemic retinoids within the past 6 months or topical retinoids within the past 6 weeks.~* Received treatment with estrogens (including oral, implanted, injected and topical contraceptives), androgens, or anti-androgenic agents for 12 weeks or less immediately prior to starting study product. Subjects who have been treated with estrogens, as described above, androgens, or anti-androgenic agents for more than 12 consecutive weeks prior to start of study product are allowed to enroll as long as they do not expect to change dose, drug, or discontinue use during the study.~* Used topical anti-acne medications (eg, BPO, azelaic acid, resorcinol, salicylates, etc.) within the past 2 weeks.~* Used abradents or facial procedures, within the past 2 weeks.~* Use medications that may exacerbate acne.~* Have a known hypersensitivity or have had previous allergic reaction to any of the active components, lincomycin, or excipients of the study product.~* Used any investigational therapy within the past 4 weeks, or currently participating in another clinical study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): clindamycin / benzoyl peroxide gel
- 2 (Type: ACTIVE_COMPARATOR): Clindamycin gel
- 3 (Type: ACTIVE_COMPARATOR): BPO gel
- 4 (Type: PLACEBO_COMPARATOR): vehicle gel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~- Advanced idiopathic Parkinson's disease~Exclusion Criteria:~- Other diseases which might influence compliance or participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Duodopa Naïve (Type: EXPERIMENTAL): Duodopa-naïve participants titrated to receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL \[100-200 mg levodopa\]); the continuous maintenance dose (usually 2-6 mL/hour \[40-120 mg levodopa/hour\]); and extra bolus doses, adjusted individually.
- Duodopa Non-naïve < 2 Years (Type: EXPERIMENTAL): Duodopa non-naïve participants treated with Duodopa for \< 2 years receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL \[100-200 mg levodopa\]); the continuous maintenance dose (usually 2-6 mL/hour \[40-120 mg levodopa/hour\]); and extra bolus doses, adjusted individually.
- Duodopa Non-naïve ≥ 2 years (Type: EXPERIMENTAL): Duodopa non-naïve participants treated with Duodopa for ≥ 2 years receive Duodopa (levodopa/carbidopa intestinal gel) adjusted to an optimal clinical response for each participant, using the portable CADD Legacy Duodopa pump (CE 0473). Treatment is composed of 3 individually adjusted doses: the morning bolus dose (usually 5-10 mL \[100-200 mg levodopa\]); the continuous maintenance dose (usually 2-6 mL/hour \[40-120 mg levodopa/hour\]); and extra bolus doses, adjusted individually.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Patients with confirmed symptomatic PE or proximal DVT of the leg(s) who have been treated for 6 to 18 months with therapeutic dosages (intended INR between 2-3) of an oral VKA (e.g. warfarin, acenocoumarol, phenprocoumon, or fluindione) or RE-COVER study medication up to the moment of screening for the current study.~2. Written informed consent~Exclusion criteria:~1. Younger then 18 years of age~2. Indication for VKA other than DVT and/or PE~3. Patients in whom anticoagulant treatment for their index PE or DVT should be continued~4. Active liver disease or liver disease decreasing survival (e.g. acute hepatitis, chronic active hepatitis, cirrhosis) or ALAT \> 3 x ULN~5. Creatinine clearance \< 30 ml/min~6. Acute bacterial endocarditis~7. Active bleeding or high risk for bleeding.~8. Uncontrolled hypertension (investigators judgement)~9. Intake of another experimental drug within the 30 days prior to randomization into the study~10. Life expectancy \<6 months~11. Childbearing potential without proper contraceptive measures\*, pregnancy or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- dabigatran etexilate 150 mg BID (Type: EXPERIMENTAL): Patient to receive dabigatran etexilatate capsules 150 mg twice daily
- matching placebo twice daily (BID) (Type: PLACEBO_COMPARATOR): Patient to receive dabigatran extexilate matching placebo capsules twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete